Although some biomarkers such as PD‐L1 levels in tumor tissue, tumor mutation burden, and CD8+ tumor‐infiltrating lymphocytes, have been reported to be predictive of the efficacy of ICIs, these markers have yet to be established due to no conclusive results across tumors.30, 31, 32. Here, CD8A is linked to neoplasm.